Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease

• Status: Completed
• Trial end date: 2018-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to evaluate the efficacy of STW5 Iberogast, over a 28-day period, for the treatment of constipation in parkinsonian patients suffering from gastrointestinal disorders.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nantes University Hospital

Criteria

Inclusion Criteria:

• Patient 30 to 80 years

• Parkinson's disease according to the criteria of the United Kingdom Parkinson's Disease Society Brain Bank

• Presence of constipation defined by the Rome III criteria Functional constipation

• Social assured Patient

• Patients with signed consent

Exclusion Criteria:

• Organic Affection colic

• Constipation Drug

• Other neurological disorder Parkinson's disease

• Metabolic disease diabetes collagenoses

• Severe renal or hepatic impairment

• Pregnant or lactating women

• Premenopausal women without contraceptive device effective

• Regular and prolonged use of history (> 12 months) of laxatives irritants

• Use of oral laxative treatment in the two weeks before the start of treatment, and refusal to stop these treatment during the course of the study

• Taking treatment antabuse

• Cognitive impairment compromising understanding or application instructions

• Patient already included in a research protocol

• Minors

• Nobody protected by law